Accelerating Medicine Partnership in Parkinsons disease (AMP PD) unbiased proteomics biofluid analysis (U01 Clinical Trials Not Allowed)

Funding Opportunity RFA-NS-19-028 from the NIH Guide for Grants and Contracts. The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from the Accelerating Medicine Partnership in Parkinson's disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data and workflows generated through this initiative will be broadly shared with the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. The proteomics analysis will be staged to include identification of pre-analytical variables, that will inform the optimal handling of 4,500 CSF and plasma samples.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding